Strontium is an alkaline earth metal that is present in small quantities in the human body (approximately 320mg in the average adult, primarily in bone, where it substitutes for calcium in the hydroxyapatite crystal lattice of bone mineral) and that has been extensively studied for its effects on bone health since the 1950s. The two clinically significant forms of strontium are strontium ranelate (the pharmaceutical form, which is used at 2g daily for the treatment of osteoporosis) and strontium chloride (the supplemental form, which is used at lower doses in nutritional supplements). Strontium ranelate has been evaluated in two large phase III RCTs (the SOTI and TROPOS trials) in postmenopausal women with osteoporosis, demonstrating approximately 40-50% reduction in vertebral fracture risk and approximately 15-20% increase in bone mineral density at the lumbar spine over 3-5 years of treatment — making it one of the most effective anti-osteoporotic agents ever tested in large clinical trials, comparable in efficacy to the bisphosphonates and superior to other nutritional approaches to bone health.
The Dual Mechanism of Strontium on Bone
The mechanism by which strontium increases bone mass and reduces fracture risk is unique among anti-osteoporotic agents — it involves the simultaneous reduction of bone resorption (by osteoclasts) and the stimulation of bone formation (by osteoblasts), a dual mechanism that is in contrast to the bisphosphonates and denosumab (which purely suppress bone resorption) and to the parathyroid hormone analogues (which purely stimulate bone formation). Strontium appears to achieve this dual effect through the calcium-sensing receptor (CaSR) on bone cells — at the concentrations achieved with oral strontium supplementation, strontium acts as a partial agonist of the CaSR, which is the primary sensor of extracellular calcium concentration on osteoclasts and osteoblasts. Activation of the CaSR on osteoclasts inhibits osteoclast formation and activity (reducing bone resorption), while activation of the CaSR on osteoblasts stimulates osteoblast proliferation and activity (increasing bone formation). This calcium-sensing mechanism explains why strontium can simultaneously reduce bone resorption and increase bone formation — two effects that are normally mutually exclusive with other anti-resorptive or anabolic agents.
The incorporation of strontium into bone is an inevitable consequence of its chemical similarity to calcium — when strontium is present in the blood at elevated concentrations (as during strontium supplementation), it is incorporated into the hydroxyapatite crystal lattice of bone in proportion to its blood concentration, substituting for calcium at the crystal surface. At the doses used in clinical trials (2g daily of strontium ranelate), this incorporation is approximately 1-2% of the total bone mineral after 3 years of treatment, which is below the threshold at which the mechanical properties of bone are compromised. However, at very high doses of strontium, the substitution of strontium for calcium in the hydroxyapatite crystal can weaken the bone mineral — a finding that is primarily relevant to the very high doses of strontium chloride that are sometimes used in nutritional supplements (which can approach the concentrations used in the pharmaceutical trials and which may produce clinically significant strontium incorporation at the higher end of the supplemental dose range).
Clinical Evidence
The clinical evidence for strontium ranelate in osteoporosis is strong. The SOTI trial (Spinal Osteoporosis Therapeutic Intervention) enrolled 1,649 postmenopausal women with osteoporosis and found that strontium ranelate at 2g daily for 3 years reduced the risk of new vertebral fractures by approximately 41% compared to placebo, with a corresponding increase in lumbar spine bone mineral density of approximately 14%. The TROPOS trial (Treatment of Osteoporosis Research) enrolled 5,091 postmenopausal women with osteoporosis and found that strontium ranelate at 2g daily for 3 years reduced the risk of new non-vertebral fractures (including hip fractures) by approximately 16% compared to placebo. Subgroup analyses of both trials showed that strontium ranelate was effective across a broad range of patient subgroups, including elderly women over 80 years of age, women with severe osteoporosis, and women with a history of fractures. The most common adverse effects of strontium ranelate are nausea, diarrhoea, and headache (which are typically mild and transient), and an approximately 2-fold increased risk of venous thromboembolism that has been attributed to the ranelate component rather than to the strontium itself.
Practical Application
For bone health support, the evidence-based dose for strontium is 680-1,000mg of elemental strontium daily from strontium citrate or strontium chloride (equivalent to approximately 2-3g of strontium salt, which provides approximately 680-1,000mg of elemental strontium). The dose used in the clinical trials of strontium ranelate was 2g daily of strontium ranelate, which provided approximately 680mg of elemental strontium — this is the dose that is supported by the clinical trial evidence. Strontium should always be taken with calcium and vitamin D to ensure that the calcium-dependent CaSR signalling that mediates the bone-forming effects of strontium is not compromised by calcium deficiency. The primary clinical indication for strontium supplementation is osteoporosis (particularly in people who cannot tolerate or do not respond to bisphosphonates or denosumab). For comprehensive bone health support, strontium pairs well with calcium (1,000-1,200mg daily), vitamin D3 (2,000-4,000 IU daily), magnesium (300-400mg daily), vitamin K2 (200mcg daily of MK-7), and boron (3-6mg daily).
A quality supplement routine can make a real difference to your results.
Leave a Reply